Welcome to our dedicated page for Aptorum Group news (Ticker: APM), a resource for investors and traders seeking the latest updates and insights on Aptorum Group stock.
Aptorum Group Limited reports developments as a pharmaceutical company focused on discovering, developing and commercializing therapeutic assets for diseases with unmet medical needs. Its disclosed program areas include oncology, including orphan oncology indications, and infectious diseases, with pipeline references such as SACT-1 for neuroblastoma and ALS-4 for bacterial infections caused by Staphylococcus aureus, including MRSA.
Recurring APM news includes clinical and regulatory disclosures, operating and financial results, material agreements, shareholder voting matters, governance updates, capital-structure disclosures and Nasdaq listing-compliance communications.
Aptorum Group Limited (NASDAQ: APM) reported a significant net loss of $17.1 million for the first half of 2021, up from $7.0 million in 2020, largely due to losses on investments. However, its clinical programs are advancing; the ALS-4 program has successfully completed the single ascending dose portion of its trial, and the SACT-1 program received FDA clearance for clinical trials. Additionally, the company has $20.1 million in cash and expects to fund operations for at least the next 12 months. R&D expenses increased due to contracted services as clinical projects progress.
Aptorum Group (Nasdaq: APM) has announced further positive results from its ongoing Phase 1 clinical trial for ALS-4, an innovative anti-virulence treatment targeting Staphylococcus aureus, including MRSA. The trial has completed two additional cohorts, C (100mg) and D (200mg), with no serious adverse events reported. All subjects in these cohorts remained in the study, indicating robust safety. The study aims to assess ALS-4’s safety, tolerability, and pharmacokinetics, with plans to advance to the multiple ascending dose stage in Q3 2021.
Aptorum Group Limited (Nasdaq: APM) announced that an interview with President Mr. Darren Lui will air on The RedChip Money Report on Bloomberg Network on July 10 at 7 p.m. U.S. Eastern. This program reaches 73 million homes in the U.S. The company focuses on developing therapeutics for unmet medical needs, particularly in oncology and infectious diseases. Additionally, Aptorum is enhancing its pipeline through new drug discovery platforms and co-developing rapid pathogen diagnostics with Accelerate Technologies.
Aptorum Group (NASDAQ: APM) announced that CEO Ian Huen has purchased 1,387,925 Class A Ordinary Shares at $2.882 each, a 10% premium over the last closing price. Huen emphasized the positive progress of the company's key programs, ALS-4 and SACT-1, during recent updates. With a focus on developing therapeutics for unmet medical needs, Aptorum continues to advance its clinical-stage pipeline and drug discovery platforms. The company is also partnering with Accelerate Technologies on a rapid pathogen detection technology.
Aptorum Group Limited (Nasdaq: APM) announced positive developments in its clinical trials. The Phase I trial for ALS-4, targeting Staphylococcus aureus, has completed initial cohorts with no serious adverse events reported. The study, which aims to evaluate ALS-4's safety and tolerability, is advancing to higher dosing cohorts. Additionally, Aptorum completed its Pre-IND meeting with the US FDA for SACT-1, a repurposed drug for neuroblastoma, and plans to submit an IND in Q3 2021. These advancements highlight Aptorum's commitment to addressing unmet medical needs.
Aptorum Group Limited (NASDAQ: APM) announced that President and Executive Director, Mr. Darren Lui, will present at the Benzinga Global Small Cap Conference on May 14, 2021, at 5:05 PM ET. The conference aims to highlight small-cap companies and their potential for growth and innovation. Aptorum Group focuses on developing therapeutics for severe medical needs, including oncology and infectious diseases. Their strategy includes drug discovery platforms and partnerships to enhance their product pipeline.
Aptorum Group (Nasdaq: APM) has partnered with Exeltis to develop a novel preclinical candidate targeting women's health issues, particularly endometriosis. The collaboration covers the European Union and Latin America, with potential expansion to the U.S. Aptorum retains development rights in other regions and aims to offer a non-hormonal treatment alternative for endometriosis, a condition affecting about 10% of women of reproductive age. The commercialization of this candidate is contingent upon regulatory approvals.
Aptorum Group Limited (Nasdaq: APM) announced an upcoming interview with President Darren Lui, to air on The RedChip Money Report on Bloomberg Network, April 24 at 7 p.m. ET. The show reaches 73 million households in the U.S., highlighting Aptorum's commitment to address unmet medical needs in oncology and infectious diseases. The company's pipeline includes drug discovery platforms and collaborations, notably with Accelerate Technologies for rapid pathogen detection diagnostics. For more details, visit www.aptorumgroup.com.
Aptorum Group Limited (Nasdaq: APM) has signed a material transfer and option agreement with Yale University to evaluate preclinical novel immunomodulators targeting autoimmune and oncology diseases. This collaboration includes a potential exclusive license to the associated intellectual property. Aptorum will assess these immunomodulators for various diseases, including lupus and arthritis, and may develop them further. CEO Ian Huen highlighted the initiative's potential to expand Aptorum's drug discovery capabilities, especially in treatments addressing cytokine storms related to COVID-19.
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) announced its 2020 financial results, reporting a net income of $4.9 million, a significant recovery from a net loss of $20.1 million in 2019. This turnaround was largely driven by a $25.2 million gain on marketable securities. The company's R&D expenses increased to $11.6 million due to advancements in project development. It remains focused on its clinical trials for ALS-4 and SACT-1, and plans to distribute a bioactive supplement in 2021. As of December 31, 2020, cash and restricted cash totaled $3.6 million, down from $5.3 million in 2019.